© 2003 European Society of Cardiology
Beta-blocker benefit according to severity of heart failure
Pharmacology Department, Pitié – Salpêtrière Hospital 47 Boulevard de l'Hôpital, 75013 Paris, France
* Corresponding author. Tel.: '33-1-42-16-16-73; fax: +33-1-42-16-16-88. E-mail address: anissa.bouzamondo{at}psl.ap-hop-paris.fr
 |
Abstract |
|---|
Background and aims: Beta-blockers are an established treatment for chronic heart failure. However, the relationship between their benefit and the severity of the disease remains to be determined.
Methods and results: We studied the relationship between amplitude of benefit of beta-blockers and severity of chronic heart failure, based on data for mortality and hospitalizations for worsening heart failure, using a meta-analysis of randomized controlled trials, complementary subgroup analyses and analysis of individual data from the CIBIS II trial. In the meta-analysis, mortality was reduced by 22% (95%CI: 16 to 28) and hospitalizations for worsening heart failure by 24% (95%CI: 20 to 29). Benefit was similar with metoprolol, bisoprolol and carvedilol. After exclusion of bucindolol trials, due to the heterogeneity of results for mortality, the reduction in mortality was similar according to the severity of heart failure, assessed either by left ventricular ejection fraction or by New York Heart Association classification. In CIBIS II, beta-blockers induced a significant reduction in mortality of 45% (95%CI: 9 to 66), 41% (95%CI: 17 to 59) and 23% (95%CI: 1 to 40) in the low, intermediate and high risk groups, respectively. Hospitalizations were reduced by 35% (95%CI: 2 to 57), 41% (95%CI: 18 to 58) and 23% (95%CI: 0 to 41), there was no significant difference between the three score groups.
Conclusion: We conclude that the amplitude of benefit of the beta-blockers carvedilol, metoprolol and bisoprolol on mortality and morbidity is similar, regardless of the severity of chronic heart failure.
Key Words: Heart failure • Meta-analysis • Prognosis • Mortality
Received June 11, 2002; Revised October 28, 2002; Accepted February 17, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Willenheimer The current role of beta-blockers in chronic heart failure: with special emphasis on the CIBIS III trial Eur. Heart J. Suppl., March 1, 2009; 11(suppl_A): A15 - A20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Orso, S. Baldasseroni, G. Fabbri, L. Gonzini, D. Lucci, C. D'Ambrosi, M. Gobbi, G. Lecchi, S. Randazzo, G. Masotti, et al. Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure Eur J Heart Fail, January 1, 2009; 11(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Metra, C. Torp-Pedersen, J. G.F. Cleland, A. Di Lenarda, M. Komajda, W. J. Remme, L. D. Cas, P. Spark, K. Swedberg, P. A. Poole-Wilson, et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET Eur J Heart Fail, September 1, 2007; 9(9): 901 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bangalore, F. H. Messerli, J. B. Kostis, and C. J. Pepine Cardiovascular Protection Using Beta-Blockers: A Critical Review of the Evidence J. Am. Coll. Cardiol., August 14, 2007; 50(7): 563 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Opasich, A. Boccanelli, M. Cafiero, V. Cirrincione, D. Del Sindaco, A. D. Lenarda, S. D. Luzio, P. Faggiano, M. Frigerio, D. Lucci, et al. Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: Results of the BRING-UP 2 Study Eur J Heart Fail, October 1, 2006; 8(6): 649 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ponikowski Rationale and design of CIBIS III Eur. Heart J. Suppl., June 1, 2006; 8(suppl_C): C35 - C42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Lee, J. V. Tu, D. N. Juurlink, D. A. Alter, D. T. Ko, P. C. Austin, A. Chong, T. A. Stukel, D. Levy, and A. Laupacis Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure JAMA, September 14, 2005; 294(10): 1240 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Abbott, F. C. Trespalacios, L. Y. Agodoa, A. J. Taylor, and G. L. Bakris {beta}-Blocker Use in Long-term Dialysis Patients: Association With Hospitalized Heart Failure and Mortality Arch Intern Med, December 13, 2004; 164(22): 2465 - 2471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Vanoli, S. Bacchini, S. Panigada, F. Pentimalli, and P. B Adamson Experimental models of heart failure Eur. Heart J. Suppl., November 1, 2004; 6(suppl_F): F7 - F15. [Abstract] [Full Text] [PDF]
|
|